简体
简体中文
繁體中文

NMP Acquisition Corp. Rights - For Shares NMPAR

等待开盘 10-21 09:30:00 美东时间

0.2305

0.000

0.00%

华盛通华盛通
立即下载
  • 最 高0.00
  • 今 开0.2305
  • 成交量 5股
  • 最 低 0.00
  • 昨 收 0.2305
  • 总市值 368.13万
  • 52周最高 0.3522
  • 市盈率 --
  • 换手率 0.00%
  • 52周最低 0.18
  • 委 比 -51.18%
  • 总股本 1597.08万
  • 历史最高 0.3522
  • 量 比 0.00
  • 振 幅 0.00%
  • 历史最低 0.18
  • 每 手 1
  • 风险率

个股概要

财务分析

公司资料

相关新闻

分红派息

  • 分时图
  • 日k
  • 周k
  • 月k

相关新闻

更多
  • Monopar Announces Abstract Accepted for Oral Presentation at AASLD - The Liver Meeting® 2025

    Monopar Therapeutics Inc. announced that its Phase 2 ALXN1840-WD-204 copper balance study abstract has been selected for oral presentation at the AASLD Liver Meeting 2025. The session, titled "Rapidly Improved Cu Balance in Wilson Disease Patients on Tiomolybdate Choline," will take place on November 9, 2025, at 9:00-9:15 am EST. For more details, visit the conference website or www.monopartx.com.

    10-15 12:00

  • Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

    Monopar Therapeutics Inc. announced the pricing of an underwritten registered offering of 1,034,433 shares of its common stock at $67.67 per share, with pre-funded warrants offered to certain investors. The gross proceeds are expected to be approximately $100 million, with $35 million allocated to purchasing shares from Tactic Pharma, LLC. The company plans to use the remaining net proceeds for general corporate purposes, including research and d...

    09-24 03:08